Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
The demographic, clinical, and laboratory characteristics of the study population are shown in Table 1.Demographic, clinical and laboratory characteristics of the study population, stratified by sex and gonadal status.Total (N = 112)FemaleMaleAll (N = 66)Eugonadal (N = 39)Hypogonadal (N = 27)All (N = 46)Eugonadal (N = 37)Hypogonadal (N = 9)Demographic and clinical characteristics Age, year35.1 ± 12.538.2 ± 13.233.0 ± 9.845.7 ± 13.9**30.8 ± 10.228.6 ± 9.539.8 ± 8.6** BMI, kg/m219.9 ± 2.720.2 ± 2.620.1 ± 2.220.5 ± 3.219.5 ± 2.919.3 ± 2.720.2 ± 3.7 β/E thalassemia (%)100 (89.3)57 (86.3)33 (84.6)24 (88.9)43 (93.5)35 (94.6)8 (88.9) Smoking, n (%)5 (4.5)2 (3.0)0 (0.0)2 (7.4)3 (6.5)3 (8.1)0 (0.0) Alcohol drinking (%)11 (9.8)6 (9.1)3 (7.7)3 (11.1)5 (10.9)4 (10.8)1 (11.1) History of falls in the past year (%)7 (6.3)5 (7.6)3 (7.7)2 (7.4)2 (4.3)0 (0.0)2 (22.2)* Splenectomy (%)46 (41.1)23 (34.8)13 (33.3)10 (37.0)23 (50.0)18 (48.6)5 (55.6) Blood transfusion, unit/years24.7 ± 9.824.5 ± 9.424.8 ± 8.424.0 ± 10.925.0 ± 10.523.5 ± 9.731.1 ± 11.9 Iron chelation (%) Deferiprone62 (55.4)33 (50.0)18 (46.2)15 (55.6)29 (63.0)26 (70.3)3 (33.3)* Deferoxamine3 (2.7)2 (3.0)0 (0.0)2 (7.4)1 (2.2)1 (2.7)0 (0.0) Deferasirox29 (25.9)20 (30.3)12 (30.8)8 (29.6)9 (19.6)6 (16.2)3 (33.3)Laboratory findings Pre transfusion Hb, g/dL7.96 ± 1.537.7 ± 1.47.58 ± 1.597.90 ± 1.068.32 ± 1.648.54 ± 1.597.42 ± 1.64 Ferritin, ng/mL1945 (1019 to 4380)2228 (1135 to 4503)2270 (833 to 4626)2204 (1340 to 4461)1545 (995 to 4248)1404 (851 to 3291)4139 (1695 to 9669)* Ferritin ≥ 1000 ng/mL (%)85 (75.9)50 (75.8)27 (69.2)23 (85.2)35 (76.1)26 (70.3)9 (100.0) FPG, mg/dL96 ± 3298 ± 4098 ± 47100 ± 2792 ± 1588 ± 8110 ± 24* Creatinine, mg/dL0.52 (0.43 to 0.63)0.50 (0.38 to 0.56)0.49 (0.38 to 0.56)0.52 (0.42 to 0.61)0.58 (0.47 to 0.67)0.58 (0.49 to 0.67)0.55 (0.37 to 0.71) Albumin, g/dL4.3 ± 0.44.3 ± 0.44.4 ± 0.34.2 ± 0.4*4.4 ± 0.44.4 ± 0.44.2 ± 0.4 Calcium, mg/dL8.9 ± 0.48.8 ± 0.48.8 ± 0.48.9 ± 0.48.9 ± 0.38.9 ± 0.38.9 ± 0.4 25(OH)D, ng/mL21.2 ± 7.619.9 ± 7.419.8 ± 7.120.3 ± 8.022.8 ± 7.623.7 ± 7.419.0 ± 7.7 Intact PTH, pg/mL36 (29 to 48)40 (32 to 52)38 (31 to 48)40 (32 to 64)34 (26 to 39)34 (27 to 39)35 (20 to 41) IGF-1, ng/mL62 (39 to 100)67 (39 to 94)76 (46 to 101)44 (28 to 87)**60 (39 to 118)72 (47 to 128)36 (17 to 47)** FSH, IU/L: 9.2 (3.2 to 36.7)7.2 (3.3 to 10.3)12.9 (2.5 to 40.9)4.0 (2.8 to 5.5)4.7 (3.1 to 5.6)1.3 (0.7 to 4.2)* LH, IU/L: 7.8 (2.4 to 14.4)8.8 (5.7 to 11.3)7.8 (1.1 to 25.5)6.8 (4.1 to 9.5)7.1 (5.2 to 10.1)2.2 (1.0 to 6.3)** Estradiol, pg/mL: 13.8 (5.0 to 45.7)90.8 (62.2 to 136.1)6.2 (5.0 to 19.2)**: : : TT, nmol/L: : : : 27.7 (19.8 to 38.8)32.2 (22.1 to 42.3)3.2 (0.7 to 11.8)** Calculated FT, %: : : 0.23 (0.28 to 0.49)0.46 (0.37 to 0.51)0.02 (0.004 to 0.12)** SHBG, nmol/L: : : : 79.8 ± 36.071.5 ± 30.3113.9 ± 39.3** CTX, ng/mL0.62 (0.44 to 0.84)0.59 (0.39 to 0.82)0.49 (0.36 to 0.73)0.66 (0.44 to 0.96)0.62 (0.48 to 0.92)0.68 (0.49 to 0.92)0.55 (0.38 to 0.79) P1NP, ng/mL54.8 (41.4 to 79.9)55.6 (40.7 to 78.8)47.7 (39.7 to 66.5)67.1 (49.1 to 88.8)**54.5 (43.2 to 90.7)54.4 (46.2 to 91.6)59.8 (36.8 to 91.1)Endocrinopathies Diabetes mellitus (%)6 (5.4)4 (6.1)2 (5.1)2 (7.4)2 (4.3)0 (0.0)2 (22.2)* Vitamin D deficiency (%)57 (50.9)40 (60.6)23 (59.0)17 (63.0)17 (37.0)12 (32.4)5 (55.6) Hypoparathyroidism (%)1 (0.9)0 (0.0)0 (0.0)0 (0.0)1 (2.2)0 (0.0)1 (11.1) Secondary/subclinical hypothyroidism (%)36 (32.2)22 (33.3)13 (33.4)9 (33.3)14 (30.4)8 (21.6)6 (66.7)** Secondary hypogonadism (%)24 (21.4)15 (22.7)0 (0.0)15 (55.6)**9 (19.6)0 (0.0)9 (100.0)**Low IGF-1 level (%)38 (33.9)16 (24.2)7 (17.9)9 (33.3)**22 (47.8)14 (37.8)8 (88.9)**Values are expressed as mean ± SD when normally distributed, as median (IQR) when not normally distributed, and as percentages when categorical.BMI body mass index, Hb hemoglobin, FPG fasting plasma glucose, 25(OH)D 25-hydroxyvitamin D, PTH parathyroid hormone, IGF-1 insulin-like growth factor 1, FSH follicle stimulating hormone, LH luteinizing hormone, TT total testosterone, FT free testosterone, SHBG sex hormone binding globulin, CTX C-terminal cross-linking telopeptide of type I collagen, P1NP procollagen type 1 N-terminal propeptide.P values by unpaired t-test, Mann: Whitney U, and Chi-square or Fisher’s exact test for parametric, non-parametric, and categorical variables respectively. *P < 0.05, **P < 0.01 versus Eugonadal.
Source: Characteristics of the study population. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Cross-sectional study.
Cross-sectional study
Examines a population at a particular point in time.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
A cross-sectional study was conducted at the hematologic clinic at King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Source: Abstract.
We included 112 TDT patients aged 35.1 ± 12.5 years.
Source: Abstract.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Association of osteoporosis and sarcopenia with fracture risk in transfusion-dependent thalassemia
Cross-sectional study · Scientific Reports · 2023
Original publication title
Association of osteoporosis and sarcopenia with fracture risk in transfusion-dependent thalassemia
© The Author(s) 2023
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Patients with transfusion-dependent thalassemia (TDT) have an increased risk of osteoporosis and fractures. They also have several potential factors associated with sarcopenia. There has been currently no study on sarcopenia and its association with falls and fractures in TDT. This study aims to determine the prevalence of and factors associated with osteoporosis, fragility fractures, and sarcopenia in adults with TDT. A cross-sectional study was conducted at the hematologic clinic at King Chulalongkorn Memorial Hospital, Bangkok, Thailand. Clinical data and laboratory testing were collected.
Bone mineral density and morphometric vertebral fracture were assessed. Sarcopenia was defined using the 2014 and 2019 Asian Working Group for Sarcopenia (AWGS) criteria. We included 112 TDT patients aged 35.1 ± 12.5 years. The prevalence of osteoporosis was 38.4%. Fragility fractures were found in 20.5% of patients. Lower BMI (OR 0.29; 95% CI 0.12 to 0.72, P = 0.007) and hypogonadal state (OR 3.72; 95% CI 1.09 to 12.74, P = 0.036) were independently associated with osteoporosis. According to the 2014 AWGS criteria, the prevalence of overall sarcopenia and severe sarcopenia was 44.6% and 13.4%, respectively.
Severe sarcopenia was strongly associated with fragility fractures (OR 4.59, 95% CI 1.21 to 17.46, P = 0.025). In conclusion, osteoporosis, fragility fractures, and sarcopenia were prevalent in adults with TDT. Severe sarcopenia was associated with fragility fractures. Early osteoporosis and sarcopenia screening and prevention may reduce fracture risk and its complications in these patients.
Authors’ abstract
Patients with transfusion-dependent thalassemia (TDT) have an increased risk of osteoporosis and fractures. They also have several potential factors associated with sarcopenia. There has been currently no study on sarcopenia and its association with falls and fractures in TDT. This study aims to determine the prevalence of and factors associated with osteoporosis, fragility fractures, and sarcopenia in adults with TDT. A cross-sectional study was conducted at the hematologic clinic at King Chulalongkorn Memorial Hospital, Bangkok, Thailand. Clinical data and laboratory testing were collected.
Bone mineral density and morphometric vertebral fracture were assessed. Sarcopenia was defined using the 2014 and 2019 Asian Working Group for Sarcopenia (AWGS) criteria. We included 112 TDT patients aged 35.1 ± 12.5 years. The prevalence of osteoporosis was 38.4%. Fragility fractures were found in 20.5% of patients. Lower BMI (OR 0.29; 95% CI 0.12 to 0.72, P = 0.007) and hypogonadal state (OR 3.72; 95% CI 1.09 to 12.74, P = 0.036) were independently associated with osteoporosis. According to the 2014 AWGS criteria, the prevalence of overall sarcopenia and severe sarcopenia was 44.6% and 13.4%, respectively.
Severe sarcopenia was strongly associated with fragility fractures (OR 4.59, 95% CI 1.21 to 17.46, P = 0.025). In conclusion, osteoporosis, fragility fractures, and sarcopenia were prevalent in adults with TDT. Severe sarcopenia was associated with fragility fractures. Early osteoporosis and sarcopenia screening and prevention may reduce fracture risk and its complications in these patients.
Publication and source details
Original title: Association of osteoporosis and sarcopenia with fracture risk in transfusion-dependent thalassemia
Suttana Thavonlun; Natnicha Houngngam; Kanaungnit Kingpetch; Numphung Numkarunarunrote; Prangareeya Santisitthanon; Patinut Buranasupkajorn; Chatlert Pongchaiyakul; Pranee Sutcharitchan; Lalita Wattanachanya
Scientific Reports · 2023
© The Author(s) 2023https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.http://dx.doi.org/10.13039/501100002873Chulalongkorn UniversityCU_GR_63_106_30_13Wattanachanya Lalita The Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn UniversityRA-MF-43/63Wattanachanya Lalita The Thai Endocrine Society Research Grants2563/04Wattanachanya Lalita The Royal College of Physicians of Thailand Grand5/2563Wattanachanya LalitaRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T16:13:37.442326+00:00
DOI: 10.1038/s41598-023-43633-6 · PMC10541420